ATE103495T1 - Pharmazeutische antigen-antikoerper-komplexe enthaltende zusammensetzungen und deren anwendungen. - Google Patents

Pharmazeutische antigen-antikoerper-komplexe enthaltende zusammensetzungen und deren anwendungen.

Info

Publication number
ATE103495T1
ATE103495T1 AT91900689T AT91900689T ATE103495T1 AT E103495 T1 ATE103495 T1 AT E103495T1 AT 91900689 T AT91900689 T AT 91900689T AT 91900689 T AT91900689 T AT 91900689T AT E103495 T1 ATE103495 T1 AT E103495T1
Authority
AT
Austria
Prior art keywords
antigen
treatment
applications
pharmaceutical compositions
compositions containing
Prior art date
Application number
AT91900689T
Other languages
English (en)
Inventor
Jean-Marie Saint-Remy
Philippe Lebrun
Serge Lebeque
Pierre Lucien Masson
Marc Jacquemin
Original Assignee
Int Inst Cellular Molecul Path
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cellular Molecul Path filed Critical Int Inst Cellular Molecul Path
Application granted granted Critical
Publication of ATE103495T1 publication Critical patent/ATE103495T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91900689T 1990-01-03 1990-12-31 Pharmazeutische antigen-antikoerper-komplexe enthaltende zusammensetzungen und deren anwendungen. ATE103495T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46051490A 1990-01-03 1990-01-03
PCT/BE1990/000074 WO1991009619A1 (en) 1990-01-03 1990-12-31 Pharmaceutical compositions containing antigen-antibody complexes and uses therefor

Publications (1)

Publication Number Publication Date
ATE103495T1 true ATE103495T1 (de) 1994-04-15

Family

ID=23829022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91900689T ATE103495T1 (de) 1990-01-03 1990-12-31 Pharmazeutische antigen-antikoerper-komplexe enthaltende zusammensetzungen und deren anwendungen.

Country Status (15)

Country Link
US (1) US7122380B1 (de)
EP (1) EP0508993B1 (de)
JP (1) JPH03227942A (de)
AT (1) ATE103495T1 (de)
AU (1) AU644400B2 (de)
CA (1) CA2015515C (de)
DE (1) DE69007799T2 (de)
DK (1) DK0508993T3 (de)
ES (1) ES2054484T3 (de)
HU (1) HUT62486A (de)
IE (1) IE65399B1 (de)
NO (1) NO922621L (de)
PL (1) PL288597A1 (de)
PT (1) PT96409A (de)
WO (1) WO1991009619A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2095956T3 (es) * 1990-09-28 1997-03-01 British Tech Group Conjugados antigeno-anticuerpo.
US5620686A (en) * 1990-09-28 1997-04-15 British Technology Group Limited Antigen-antibody conjugates
NZ263102A (en) * 1993-03-19 1997-05-26 Immunex Corp Pharmaceutical compositions comprising a ligand protein such as interleukin-4 and a soluble receptor protein that binds thereto
FR2728264B1 (fr) * 1994-12-16 1997-01-31 Rhone Poulenc Rorer Sa Purification d'adn par formation de triple helice avec un oligonucleotide immobilise
AUPO269996A0 (en) * 1996-10-01 1996-10-24 Walter And Eliza Hall Institute Of Medical Research, The A method of prophylaxis and treatment
AU1267501A (en) * 1999-09-07 2001-04-10 Bioserv Ag Novel autogenous vaccines used to obtain an immune tolerance
AU2003232872A1 (en) 2002-05-27 2003-12-12 Ostergotlands Lans Landsting Method for determining immune system affecting compounds
CN1863555A (zh) 2003-08-15 2006-11-15 卡尔加里大学理事会 操作哺乳动物中抗原特异性抗体的水平的组合物和方法
AU2011218660B2 (en) * 2003-08-15 2011-12-15 The Governors Of The University Of Calgary Compositions and methods for manipulating levels of antigen-specific antibodies in a mammal
SE0402536D0 (sv) 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
EP1875246B1 (de) 2005-04-15 2016-10-05 CanImGuide Therapeutics AB Diagnoseverfahren zum nachweis von krebs durch messen der menge eines cytokinähnlichen il-6
GB2440528A (en) * 2006-07-27 2008-02-06 Ist Superiore Sanita Antigen-antibody complexes
ES2608803T3 (es) 2007-05-08 2017-04-17 Canimguide Therapeutics Ab Estructuras inmunorreguladoras procedentes de proteínas naturales
WO2017218677A2 (en) * 2016-06-14 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Identification and medical applications of anti-citrullinated-protein antibodies in rheumatoid arthritis
GB201802338D0 (en) 2018-02-13 2018-03-28 Univ Oslo Antigen binding proteins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140679A (en) 1976-10-12 1979-02-20 Research Corporation Antigen-protein complex for blocking allergic reactions
US4234569A (en) 1978-10-04 1980-11-18 The Johns Hopkins University Production of aldehyde-treated allergen-containing substances
DE2846412A1 (de) 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen
US4521405A (en) 1982-05-17 1985-06-04 John McMichael Methods and materials for treatment of disease states involving immunological factors
US4545986A (en) 1982-06-22 1985-10-08 Research Corporation Timothy grass antigen specific anti-idiotypic antibodies
US4564600A (en) 1982-10-26 1986-01-14 Majid Ali Allergens and antibodies from allergen extracts and pooled serum
US4702907A (en) 1983-08-09 1987-10-27 Cornell Research Foundation, Inc. Process for inducing selective immunosuppression of antibodies
US4681760A (en) 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
US4714759A (en) 1985-12-02 1987-12-22 Whitaker Jr Robert B Immunotoxin therapy of allergy
GB8608068D0 (en) 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
GB8610983D0 (en) 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
DE68925899T2 (de) * 1988-04-04 1996-10-02 Byron E Anderson Bindung von immunkomplexen durch modifizierte formen von c-reaktiven proteinen

Also Published As

Publication number Publication date
DE69007799T2 (de) 1994-10-20
AU644400B2 (en) 1993-12-09
EP0508993A1 (de) 1992-10-21
NO922621L (no) 1992-09-02
PL288597A1 (en) 1991-08-12
WO1991009619A1 (en) 1991-07-11
PT96409A (pt) 1991-10-15
HU9202214D0 (en) 1992-10-28
NO922621D0 (no) 1992-07-02
CA2015515C (en) 1999-12-07
AU6962691A (en) 1991-07-24
IE65399B1 (en) 1995-10-18
DK0508993T3 (da) 1994-05-09
IE904693A1 (en) 1991-07-17
CA2015515A1 (en) 1991-07-03
JPH03227942A (ja) 1991-10-08
DE69007799D1 (de) 1994-05-05
ES2054484T3 (es) 1994-08-01
US7122380B1 (en) 2006-10-17
HUT62486A (en) 1993-05-28
EP0508993B1 (de) 1994-03-30

Similar Documents

Publication Publication Date Title
ATE103495T1 (de) Pharmazeutische antigen-antikoerper-komplexe enthaltende zusammensetzungen und deren anwendungen.
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
RU2221590C2 (ru) Приматизированное моноклональное антитело или его фрагмент, которое специфически связывается с антигеном cd80 человека (варианты), способ лечения заболевания, связанного со взаимодействием т-клеток и в-клеток, и фармацевтическая композиция
CO4850562A1 (es) Proceso para producir una preparacion concentrada de anticuerpos
EP0735893A4 (de) Veränderung der immunantwort durch verwendung von pan dr-bindeproteinen
HUP9802199A1 (hu) Poliszacharid antigén-vivőprotein konjugátumot és szabad vivőproteint tartalmazó oltóanyag és alkalmazása
FR2516794B1 (fr) Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
FI960102A0 (fi) Uusi farmaseuttinen seos
MY111682A (en) Altered antibodies and their preparations.
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
FR2697841B1 (fr) Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
DK0969873T3 (da) Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
CA2055615A1 (en) Monoclonal antibodies for inducing tolerance
ATE205480T1 (de) 2,5-dioxo-2,5-dihydro-1h-benz(b)azepine als nmda rezeptor antagonisten
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
FR2697019B1 (fr) Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
SG48816A1 (en) Gonococcal anti-idiotypic antibodies and methods and compositions using them
EP0817650A4 (de) Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
FR2705671B1 (fr) Nouveaux dérivés de l'hydroxybiphényle, leur préparation et les compositions pharmaceutiques qui les contiennent.
CA2157500A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
WIGZELL Cellular immunosorbents
OA09439A (fr) "Nouveaux dérivés benzoxazolinoniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent".
ATE28566T1 (de) Zellgiftiges arzneimittel enthaltend mindestens ein immunotoxin und ein amin.
KR900011477A (ko) 항-트립타아제 항체 및 이것을 사용한 후천성 면역결핍증 치료용 조성물

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee